NeoGenomics (NEO) reports Q1 2026 revenue of $155M, up 27%. Adjusted EBITDA reaches $36.2M, with strong growth in rare metals and strategic initiatives.

Key Takeaways

• Revenue for Q1 2026 reached $155 million, up 27% year-over-year.
• Adjusted EBITDA was $36.2 million, more than double the $17.1 million reported in Q1 2025.
• The company raised its full-year adjusted EBITDA guidance from $75-$80 million to $100-$110 million.
• Magnaquench segment saw a 46% increase in revenue, reaching $64.7 million.
• Hafnium prices soared to $13,500 per kilogram, marking a 265% increase year-over-year.

Financial Performance

NeoGenomics, Inc. demonstrated exceptional financial performance in the first quarter of 2026, building on the momentum from previous years. The company's revenue surged to $155 million, marking a 27% increase compared to the same period last year. This growth reflects resilient demand across its core businesses and a favorable pricing environment. Adjusted EBITDA reached an impressive $36.2 million, more than doubling from $17.1 million in Q1 2025. This quarter's results are noteworthy as they represent the highest EBITDA in the company's history, driven by significant contributions from the rare metals business, Magnaquench, and Chemicals and Oxides segments.

The Magnaquench segment performed particularly well, achieving a 46% revenue increase to $64.7 million, supported by strong end-market demand. The Chemicals and Oxides segment also reported growth, delivering an adjusted EBITDA of $7.7 million, up 12% year-over-year.

Strategic Initiatives

NeoGenomics is strategically positioned for growth with several key initiatives underway. The company's rare metals business, including hafnium, gallium, tantalum, and niobium, is experiencing unprecedented demand. Hafnium prices have skyrocketed, moving from $3,700 per kilogram to $13,500 in just one year, primarily due to supply constraints and regulatory challenges surrounding production.

In addition, the company has made significant strides in its European operations. The successful launch of a small-scale heavy rare earth separation line in Europe has further reinforced its position in the market. This initiative aims to build a vertically integrated rare earth magnetics value chain, enhancing the company's capabilities in both light and heavy rare earth processing. The company is also ramping up production at its European Permanent Magnet Facility, having achieved a major milestone with the production of its one millionth magnet.

Furthermore, NeoGenomics has embarked on a multi-year research partnership with Tallinn University of Technology to integrate artificial intelligence into its operations. This collaboration aims to enhance product development and manufacturing processes, ensuring the company remains at the forefront of innovation in the critical materials sector.

Future Outlook

Looking ahead, management has raised its full-year adjusted EBITDA guidance to $100-$110 million, up from the previous estimate of $75-$80 million. This revision is based on the strong performance in Q1 and continued favorable market conditions across all business units. The company is optimistic about sustaining its growth trajectory, driven by sustained demand from high-growth sectors such as automotive, industrial applications, and renewable energy.

NeoGenomics is also focused on securing long-term contracts with customers to stabilize revenue streams, especially in the hafnium and gallium segments. The management team highlighted that while contracted volumes have been lower than historical norms, an uptick in customer contracts is anticipated as market conditions improve.

The company’s European initiatives are expected to yield significant benefits, positioning it as a key player in the global critical materials supply chain. As the world increasingly shifts towards localized supply chains, NeoGenomics’ strategic investments in its production capabilities and technological advancements will likely enhance its competitive advantage.

Closing Assessment

In summary, NeoGenomics, Inc. has delivered robust financial results for Q1 2026, showcasing its operational excellence and strategic foresight. The company's strong performance across multiple segments, coupled with increased guidance for the year, reflects a positive outlook. With ongoing investments in innovation and production capabilities, NeoGenomics is well-positioned to capitalize on the evolving landscape of the critical materials market. The combination of rising demand, favorable pricing, and strategic partnerships underpins a promising future for the company.

This analysis is based on public earnings call materials and is not investment advice.